Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.
This text is for block level content. P tags can go in here too
Find information on the development of the ACRODAT, adding and evaluating patients and visit data
Find information on funding, initiation, homecare and follow-up
Find information for your patients on the updated storage conditions for Somavert allowing vials to be kept at room temperature for a single period of up to 30 days
To find out more about ACRODAT, supporting your patients, or to order starter kits
Watch and listen to our Rare Disease Insight series where expert speakers take a deep dive into the co-morbidities associated with acromegaly
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020